News, Events & Resources
Trusted information, expert resources, and the latest from the MCL community.
News & Research Updates
Inaugural Scientific Advisory Board
Mantle Cell Lymphoma Alliance Announces Inaugural Scientific Advisory Board
MCLA has formed its inaugural Scientific Advisory Board—eleven internationally recognized physicians and researchers from premier cancer centers across North America and Europe, chaired by Dr. Tycel Phillips of City of Hope. The board will guide MCLA's scientific priorities, advise on educational initiatives, and identify promising research and grant funding opportunities.
MCLA's Report on the 2026 EHA Congress
EHA 2026: Key Mantle Cell Lymphoma Takeaways
MCLA highlights key mantle cell lymphoma research from the 2026 European Hematology Association Congress, including new CAR-T approaches, sonrotoclax combination data, and rituximab maintenance after BR.
June 2026 Newsletter
June 2026 Newsletter
Second edition of the MCLA newsletter: launching MCLA Voices, a patient story from board member Kris Tuchek, major MCL research updates from ASCO and EHA, and a look at what's coming next.
MCLA's Report on the 2026 ASCO Conference
Three Takeaways from the Recent American Society for Clinical Oncology (ASCO) Conference for MCL Patients
MCLA highlights three presentations from the 2026 ASCO Annual Meeting with direct relevance to MCL patients: long-term Glofitamab follow-up, real-world Breyanzi outcomes, and early results from a novel in vivo CAR-T approach.
Sonrotoclax
Next-Generation Therapy Sonrotoclax Receives FDA Approval
Newly approved therapy expands treatment choices and signals continued progress for people living with MCL. Sonrotoclax (brand name Beqalzi) is the first BCL-2 inhibitor formally approved for mantle cell lymphoma, cleared for patients whose disease has returned or stopped responding after at least two prior treatments.
Mosunetuzumab + Polatuzumab vedotin
Targeted Immunotherapy Combo Shows Strong Results in Relapsed Mantle Cell Lymphoma
A new Phase 2 study published in Blood in April 2026 reports an 88% response rate for a fixed-duration combination of mosunetuzumab and polatuzumab vedotin in patients with mantle cell lymphoma whose disease has returned after a BTK inhibitor.
Tecartus
FDA Grants Full Approval to Tecartus for Relapsed Mantle Cell Lymphoma
New long-term data from the ZUMA-2 trial supported the FDA's full approval of Tecartus in April 2026, with a 91% response rate in adults with relapsed or refractory mantle cell lymphoma after prior therapies including BTK inhibitors.
Acalabrutinib + Venetoclax + Rituximab
FDA Launches Real-Time Clinical Trial Pilot — and Mantle Cell Lymphoma Is at the Center
The FDA has selected a mantle cell lymphoma study as one of the first trials in a new pilot program that lets regulators see clinical trial data in real time — a move that could speed access to promising treatments for patients.
Our Story - How MCLA started
When mantle cell lymphoma changes your world overnight, you go searching for answers. Too often, you don't find them. This is the story of why we built MCLA—and what comes next.
Start with trusted, up-to-date information
Resources we recommend to almost every newly diagnosed patient and caregiver.
NCCN Guidelines for Patients®: Mantle Cell Lymphoma 2026
A 56-page plain-language guide produced by the National Comprehensive Cancer Network® — a not-for-profit alliance of 34 leading cancer centres devoted to patient care, research, and education.
Videos Worth Watching
for MCL 2026
Memorial Sloan Kettering
Dr. Anita Kumar · Memorial Sloan Kettering
Initial Treatment for MCL 2026
Watch this talk by Dr. Anita Kumar (Memorial Sloan Kettering), recorded May 2026: Initial Treatment for MCL 2026. This is an excellent, accessible overview of front-line treatment options.
Watch the recording →& High-Risk Patients
Mayo Clinic
Dr. Yucai Wang · Mayo Clinic
Changes in Treatment & Treatment for High-Risk Patients
This more technical talk by Dr. Yucai Wang (Mayo Clinic), recorded March 2025, summarizes the latest research presented at the 2024 American Society of Hematology conference.
Watch the recording →